George J Eiermann

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice

G. Scapin, J. Berger, N. Thornberry, 2017, Endocrinology, diabetes & metabolism.

Discovery of potent and selective orally bioavailable beta-substituted phenylalanine derived dipeptidyl peptidase IV inhibitors.

Joseph L Duffy, Aleksandr Petrov, N. Thornberry, 2005, Bioorganic & medicinal chemistry letters.

4-aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV.

Joseph L Duffy, G. Scapin, N. Thornberry, 2007, Bioorganic & medicinal chemistry letters.

4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV.

Joseph L Duffy, G. Scapin, N. Thornberry, 2007, Bioorganic & medicinal chemistry letters.

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

A. Woods, D. Zaller, N. Thornberry, 2005, Diabetes.

Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.

Aleksandr Petrov, N. Thornberry, B. Leiting, 2006, Bioorganic & medicinal chemistry letters.